Efinaconazole, sold under the brand name Jublia among others, is a
triazole antifungal medication. It is approved for use in the United States, Canada, and Japan as a 10% topical solution for the treatment of
onychomycosis (fungal infection of the
nail).[3][4] Efinaconazole acts as a
14α-demethylaseinhibitor.[5][2]
In two
clinical trials 17.8% (trial 1) and 15.2% (trial 2) of participants using efinaconazole were completely cured (0% clinical involvement of the target toenail, plus negative
KOH test and negative culture), compared with 3.3% (trial 1) and 5.5% (trial 2) of participants using a
placebo.[2] The "complete cure or almost complete cure" rate (≤5% affected target toenail area involved, and negative KOH and culture) for efinaconazole was 26.4% (trial 1) and 23.4% (trial 2) (compared with 7.0% (trial 1) and 7.5% (trial 2)).[2]
In 2020, the FDA approved a supplemental
New Drug Application for efinaconazole topical solution, 10%, which extended the age range included in the product's label to children six years of age and older; it was first approved in 2014, in people aged 18 years of age and older.[12]
Society and culture
Economics
In 2015, the cost of treatment with efinaconazole in the United States was said to be US$2,307 per nail.[13]
^"Archived copy"(PDF).
Archived(PDF) from the original on 10 June 2022. Retrieved 10 June 2022.{{
cite web}}: CS1 maint: archived copy as title (
link)